Recent developments in modulating chemokine networks

Bibliography

• SCHVVARZ MK, WELLS TNC: Interfering with chemokine networks - the hope for new therapeutics. Curr. Opin. Chem. Biol. (1999) 3:407–417.
   Google Scholar
• •This review summarises the biological data available to date validating chemokine receptors as drug discovery targets of therapeutic interest.
   Google Scholar
• WELLS TNC, POWER CA, PROUDFOOT AEI: Definition,function and pathophysiological significance of chemokine receptors. Trends Pharmacol. ScL (1998) 19:376–380.
   Google Scholar
• CACALANO G, LEE J, KIKLY K et al.: Neutrophil and B-cellexpansion in mice that lack the murine IL-8 receptor homolog. Science (1994) 265:682–684.
   PubMed Web of Science ®Google Scholar
• FOLKESSON HG, MATTHAY MA, HEBERT CA et al:Acid-aspiration induced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms. J. Clin. Invest. (1995) 96:107–116.
   PubMed Web of Science ®Google Scholar
• SEKIDO N, MUKAIDA N, HARADA A et al.: Prevention oflung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature (1993) 365:654–657.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO T, YOKOI K, MUKAIDA N et al.: Pivotal role of interleukin-8 in the acute respiratory distress syndrome and cerebral reperfusion injury. J. Leukocyte Biol. (1997) 62:581–587.
   PubMedGoogle Scholar
• ZAGORSKI J, WAHL SM: Inhibition of acute peritoneal inflammation in rats by a cytokine induced neutrophil chemoattractant receptor antagonist. J. Immunol. (1997) 159:1059–1062.
   PubMed Web of Science ®Google Scholar
• ZHOU Y, KURIHARA T, RYSECK RO et al: Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major 11IV-1 coreceptor. J. Immunol (1998) 160:4018–4025.
   PubMed Web of Science ®Google Scholar
• BORING L, GOSLING J, CLEARY M etal.: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature (London) (1998) 394:894–897.
   Google Scholar
• ••This is a validation in an animal model of the long-heldhypothesis that MCP-1 acts to recruit monocytes to athero-sclerotic plaques and that the MCP-1 receptor (CCR-2) is a target for therapy in atherosclerosis.
   Google Scholar
• GU L, OKADA Y, CLINTON SK et al.: Absence of monocyte chemoattractant protein-1 reduces athero-sclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. (1998) 2:275–281.
   PubMed Web of Science ®Google Scholar
• GONZALO JA, LLOYD CM, KREMER J et al.: Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T-cells, chemokines and adhesion receptors. J. Clin. Invest. (1996) 98:2332–2345.
   Google Scholar
• ROTHENBERG ME, MACLEAN JA, PEARLMAN E et al.: Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J. Exp. Med. (1997) 185:785–790.
   PubMed Web of Science ®Google Scholar
• CAMPBELL JJ, HARALDSEN G, PAN J et al.: The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature (London) (1999) 400:776–780.
   PubMed Web of Science ®Google Scholar
• AKESON AL, WOODS CW, HSIEH LC et al.: AF12198, anovel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. J. Biol. Chem. (1996) 271:30517–30523.
   PubMed Web of Science ®Google Scholar
• TIAN SS, LAMP P, KING AG et al.: A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science (1999) 281:257–259.
   Google Scholar
• ••This paper describes the first example of a non-peptidesmall molecule cytokine mimic.
   Google Scholar
• CHO N, HARADA M, IMAEDA T et al: Discovery of anovel, potent and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRID receptor. J. Med. Chem. (1998) 41:4190–4195.
   PubMed Web of Science ®Google Scholar
• ABE Y, KAYAKIRI H, SATOH S et al.: A novel class oforally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man. J. Med. Chem. (1998) 41:4055–4061.
   Google Scholar
• •This paper describes the identification of the first potent, orally active bradykinin antagonist.
   Google Scholar
• CHORVAT RJ, BAKTHAVATCHALAM R, BECK JP et al: Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo, and pyrrolopyrimidines and -pyridines. J. Med. Chem. (1999) 42:833–848.
   PubMed Web of Science ®Google Scholar
• HALE JJ, MILLS SG, MACCOSS M et al.: Structural optimi-zation affording 2- (R)-(1- (R)-3,5-bis(trifluoro-methyfiphenylethoxy)-3- (S)-(4-fluorc)pheny1-4-(3-o xo-1,2,4-triazol-5-yOmethylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J. Med. Chem. (1998) 41:4607–4614.
   PubMed Web of Science ®Google Scholar
• BELL IM, ERB JM, FREIDINGER RM et al.: Development of orally active oxytocin antagonists: studies on 1- (1 -(441- (2-methyl-1-oxidopyridin-3-ylmethy0 piperidin-4-yloxy]-2-methoxybenzoyfipiperidin-4-34)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. J. Med. Chem. (1998) 41:2146–2163.
   PubMed Web of Science ®Google Scholar
• DELASZLO SE, HACKER C, LI B et al: Potent, orally absorbed glucagon receptor antagonists. Bioorg. Med. Chem. Lett. (1999) 9:641–646.
   Google Scholar
• ASTLES PC, BROWN TJ, COX P et al.: New non peptidicC5a receptor antagonists. Bioorg. Med. Chem. Lett. (1997) 7:907–912.
   Web of Science ®Google Scholar
• PROUDFOOT AEI, WELLS TNC, CLAPHAM PR: Chemokine receptors - future therapeutic targets for HIV? Biochem. Pharmacol. (1999) 57:451–463.
   Google Scholar
• HORUK R: Chemokine receptors and 11IV-1: the fusionof two major research fields. Immunol Today (1999) 20:89–94.
   PubMedGoogle Scholar
• FENG Y, BRODER CC, KENNEDY PE et al: 11IV-1 entrycofactor: functional cDNA cloning of a seven-transmembrane, G-protein coupled receptor. Science (1996) 272:872–877.
   PubMed Web of Science ®Google Scholar
• DENG H, LIU R, ELLMEIER W et al: Identification of amajor co-receptor for primary isolates of 11IV-1. Nature (1996) 381:661–666.
   PubMed Web of Science ®Google Scholar
• DRAGIC T, LITWIN V, ALLAWAY GP et al: 11IV-1 entryinto CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381:667–673.
   PubMed Web of Science ®Google Scholar
• SAMSON M, LIBERT F, DORANZ BJ et al.: Resistance to11IV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 382:722–725.
   PubMed Web of Science ®Google Scholar
• LIU R, PAXTON WA, CHOE S eta].: Homozygous defect in11IV-1 coreceptor accounts for resistance of some multiply-exposed individuals to 11IV-1 infection. Cell (1996) 86:367–377.
   Google Scholar
• DEAN M, CARRINGTON M, WINKLER C et al: Genetic restriction of 11IV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Science (1996) 273: 1856-1862.
   Google Scholar
• SORENSEN TL, TANI M, JENSEN J et al: Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. Clin. Invest. (1999) 103:807–815.
   Google Scholar
• ••With [33], these papers discuss critical observations of therole of chemokines and their receptors in multiple sclerosis. The data fit well with what should be expected of a T-helper lymphocyte type-1 mediated disease.
   Google Scholar
• YING S, ROBINSON DS, MENG Q etal.: Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyper- responsive-ness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur. j Immunol. (1997) 27:3507–3516.#
   Google Scholar
• ••With [51], these papers report the identification and in vivobiological evaluation of a potent peptide antagonist of RANTES receptors, MetRANTES, which is nowadays used as a reference compound in target validation studies and/or drug discovery programs involving a variety of CC chemokine receptors.
   Google Scholar
• BALASHOV KE, ROTTMAN JB, WEINER HL et al.: CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-la and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA (1999) 96:6873–6878.
   PubMed Web of Science ®Google Scholar
• ••See note for [31].
   Google Scholar
• KARPUS WJ, KENNEDY KJ: MIP-la and MCP-1 differen-tially regulate acute and relapsing autoimmune encephalomyelitis as well as Thl/Th2 lymphocyte differentiation. J. Leukoc. Biol. (1997) 62:681–687.
   PubMed Web of Science ®Google Scholar
• GONZALO J-A, LLOYD CM, WEND et al: The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsive-ness. J. Exp. Med. (1998) 188:157–167.
   Google Scholar
• ••This is a comparison of the effects of blocking differentchemokines and receptors in an in vivo model of asthma.
   Google Scholar
• MENDEZ MJ, GREEN LL, CORVALAN JR et al.: Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nature Gen. (1997) 15:146–156.
   PubMed Web of Science ®Google Scholar
• SMITH LS: Virus proteins that bind cytokines, chemokines or interferons. Curr. Opin. Immunol. (1996) 8:467–471.
   PubMedGoogle Scholar
• ALCAMI A, SYMONS JA, COLLINS PD et al: Blockade ofchemokine action by a soluble chemokine binding protein from vaccinia virus. J. Immunol. (1998) 160:624–633.
   PubMed Web of Science ®Google Scholar
• •With [39], these papers identify viral proteins that bind chemokines with subnanomolar potency. The proteins themselves may be therapeutically useful, and the structure of the chemokine protein complex may give hints for drug design.
   Google Scholar
• LALANI AS, MASTERS J, GRAHAM K et al.: Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis. Virology (1999) 256:233–245.
   Google Scholar
• •See notes for [38].
   Google Scholar
• SMITH CA, SMITH TD, SMOLAK PJ et al.: Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology (1997) 236:316–327.
   PubMedGoogle Scholar
• USCHERT GS, HOOGEWERF AJ, PROUDFOOT AEI et al.: Identification of glycosaminoglycan binding surface on human interleukin-8. Biochemistry (1998) 37:11193–11201.
   Google Scholar
• MOSER B, DEWALD B, BARELLA L et al.: Interleukin-8antagonists generated by N-terminal modification. J. Biol. Chem. (1993) 268:7125–7128.
   PubMed Web of Science ®Google Scholar
• HEBERT CA, VITANGCOL RV, BAKER JB: Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J. Biol. Chem. (1991) 266:18989–18994.
   PubMed Web of Science ®Google Scholar
• JONES SA, DEWALD B, BAGGIOLINI M: Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2. J. Biol. Chem. (1997) 272:16166–16169.
   PubMed Web of Science ®Google Scholar
• GONG JH, UGUCCIONI M, DEWALD B et al.: RANTES andMCP-3 antagonists bind multiple chemokine receptors. J. Biol. Chem. (1996) 271:10521–10527.
   PubMed Web of Science ®Google Scholar
• GONG JH, CLARK-LEWIS I: Antagonists of monocytechemoattractant protein 1 identified by modification of functionally critical N112-terminal residues. J. Exp. Med. (1995) 181:631–640.
   PubMed Web of Science ®Google Scholar
• GONG JH, RATKAY LG, WATERFIELD JD et al.: An antago-nist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-/pr mouse model. J. Exp. Med. (1997) 186:131–137.
   PubMed Web of Science ®Google Scholar
• YLISASTIGUI L, VIZZAVONA J, DRAKOPOULOU E et al.:Synthetic full length and truncated RANTES inhibit 11IV-1 infection of primary macrophages. AIDS (1998) 12:977–984.
   PubMed Web of Science ®Google Scholar
• ARENZANA-SEISDEDOS F, VIRELIZIER JL, ROUSSET D etal.: HIV blocked by HIV chemokine antagonist. Nature (1996) 383:400.
   Google Scholar
• SCHOLS D, PROOST P, STRUYF S et al.: CD26-processedRANTES(3_68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res. (1998) 39:175–187.
   PubMed Web of Science ®Google Scholar
• PROUDFOOT AEI, POWER CA, HOOGEWERF AJ et al.: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol Chem. (1996) 271:2599–2603.
   PubMed Web of Science ®Google Scholar
• ••See note for [32].
   Google Scholar
• PLATER-ZYBERK C, HOOGEWERF AJ, PROUDFOOT AEI et al.: Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett. (1997) 57:57–60.
   Google Scholar
• LLOYD CM, MINTO AW, DORF ME et al.: RANTES and monocyte chemoattractant protein 1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med. (1997) 185:1371–1380.
   PubMed Web of Science ®Google Scholar
• OFFORD RE, GAERTNER HF, WELLS TNC et al.: Synthesis and evaluation of fluorescent chemokines labeled at the amino terminal. Methods Enzymol. (1997) 287:348–369.
   PubMed Web of Science ®Google Scholar
• ALOUANI S, GAERTNER HF, MERMOD J-J et al: A fluores-cent interleukin-8 receptor probe produced by targeted labeling at the amino terminus. Eur. J. Biochem. (1995) 227:328–34.
   Google Scholar
• SOLARI R, OFFORD RE, REMY S et al: Receptor-mediated endocytosis of CC-chemokines. J. Biol Chem. (1997) 272:9617–20.
   Google Scholar
• SIMMONS G, CLAPHAM PR, PICARD L eta].: Potent inhibi-tion of 11IV-1 infectivity in macrophages and lympho-cytes by a novel CCR5-antagonist. Science (1997) 276:276–279.
   Google Scholar
• MACK M, LUCKOW B, NELSON PJ et al.: Aminooxypentane-RANTES induces internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. Exp. Med. (1998) 187:1215–1224.
   PubMed Web of Science ®Google Scholar
• •With [59], these papers show differences in the signalling pathways that may be crucial for control of receptor cycling.
   Google Scholar
• OPPERMANN M, MACK M, PROUDFOOT AEI et al: Differ- ential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus. J. Biol. Chem. (1999) 274:8875–8885.
   PubMedGoogle Scholar
• •See note for [58].
   Google Scholar
• MOSIER DE, PICCHIO GR, GULIZIA RJ et al.: Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Vim]: (1999) 73:3544–3550.
   Google Scholar
• WELLS TNC, SCHWARTZ TW: Plagiarism of the host immune system: lessons about chemokine immunology from viruses. Curr. Opin. Biotechnol. (1997) 8:741–748.
   Google Scholar
• KLEDAL TN, ROSENKILDE MM, COULIN F et al.: A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science (1997) 277:1656–1659.
   PubMed Web of Science ®Google Scholar
• BOSHOFF C, ENDO Y, COLLINS PD et al.: Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science (1997) 278:290–294.
   PubMed Web of Science ®Google Scholar
• SOZZANI S, LUINI W, BIANCHI G et al.: The viral chemokine macrophage inflammatory protein-II is a selective T112 chemoattractant. Blood (1998) 92:4036–4039.
   PubMed Web of Science ®Google Scholar
• CHEN S, BACON KB, LI L et al.: In vivo inhibition of CC and CX3C chemokine induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar- Kyoto (WKY) rats byJ. Exp. Med. (1998) 188:93–198.
   Google Scholar
• MELLOR GW, FOGARTY SJ, O'BRIEN MS et al: Searchingfor chemokine receptor binding antagonists by high throughput screening. J. BiomoL Screen. (1997) 2:153–157.
   Google Scholar
• MCKINNON M, PROUDFOOT AEI, WELLS TNC et al: Strategies for the discovery of cytokine receptor antagonists. Drug News Perspect. (1996) 9:389–398.
   Google Scholar
• WHITE JR, LEE JM, YOUNG PR et al: Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. (1998) 273:10095–10098.
   PubMed Web of Science ®Google Scholar
• ••This is the first publication of a small molecule inhibitor of achemokine receptor - confirming that chemokines may be the rare cytokine receptors for which small molecule antagonists with nanomolar potency can be found.
   Google Scholar
• QUAN JM, MARTIN TR, ROSENBERG GB et al.: Antibodiesagainst the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis. Biochem. Biophys. Res. Commun. (1996) 219:405–411.
   PubMed Web of Science ®Google Scholar
• BRIGHT C, BROWN TJ, COX P et al.: Identification of anon peptidic RANTES antagonist. Bioorg. Med. Chem. Lett. (1998) 8:771–774.
   Google Scholar
• HESSELGESSER J, NG HP, LIANG M et al: Identificationand characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J. Biol. Chem. (1998) 273:15687–15692.
   PubMed Web of Science ®Google Scholar
• SAUNDERS J, TARBY CM: Opportunities for noveltherapeutic agents acting at chemokine receptors. Drug Discover)/ Today (1999) 4:80–92.
   PubMed Web of Science ®Google Scholar
• OHWAKI K, SAEKI T, AOKI I et al.: Role of CCR-1 inmurine collagen-induced arthritis: effect of a novel, potent and nonpeptidyl CCR1 antagonist, J-113863. Institut Pasteur European Conference. Paris, France (1999) Poster.
   Google Scholar
• LAPIERRE J-M: MCP-1 receptor antagonists 26th NationalMedicinal Chemistry Symposium (Part I), Richmond, VA, USA (1998) ID db Meeting Report 290619.
   Google Scholar
• GARRED P, EUGEN-OLSEN J, IVERSEN AK et al.: Dualeffect of CCR5 delta 32 gene deletion in 11IV-1-infected patients. Lancet (1997) 349:1884.
   Google Scholar
• SCHOLS D, STRUYF S, VAN DAMME J et al.: Inhibition ofT-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. (1997) 186:1383–1388.
   Google Scholar
• DONZELLA GA, SCHOLS D, LIN SW et al.: AMD3100, asmall molecule inhibitor of 11IV-1 entry via the CXCR4 co-receptor. Nature Med. (1998) 4:72–77.
   PubMed Web of Science ®Google Scholar
• BABA M, NISHIMURA O, KANZAKI N et al.: A small-molecule, nonpeptide CCR5 antagonists with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA (1999) 96:5698–5703.
   Google Scholar
• •This is the first report on a highly potent non-peptidic small molecule antagonist of CCR5, shown to inhibit the replica-tion of HIV-1 clinical isolates in PBMCs at low nanomolar concentrations.
   Google Scholar